Drug name - Tradjenta

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(2 years from now)

CN101503408B BOEHRINGER INGELHEIM 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compounds
Aug, 2023

(10 months from now)

CN1675212A BOEHRINGER INGELHEIM 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Its Purpose As A Pharmaceutical Preparation
Aug, 2023

(10 months from now)

CN102964347B BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament
Aug, 2023

(10 months from now)

CN102964347A BOEHRINGER INGELHEIM 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compound, Preparation Method And Use Thereof As Pharmaceutical Preparation
Aug, 2023

(10 months from now)

CN101503409A BOEHRINGER INGELHEIM 8-(3-Amino-Piperidin-1-Yl)-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2023

(10 months from now)

CN105001222B BOEHRINGER INGELHEIM 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation
Aug, 2023

(10 months from now)

CN100522962C BOEHRINGER INGELHEIM 8 - [3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation
Aug, 2023

(10 months from now)

CN101503409B BOEHRINGER INGELHEIM 8 - [3-Amino-Piperidin-L-Yl] - Xanthines, Processes For Their Preparation And Their Use As Pharmaceutical Preparations
Aug, 2023

(10 months from now)

CN105001222A BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament
Aug, 2023

(10 months from now)

CN101503408A BOEHRINGER INGELHEIM 8-(3-Amino-Piperidin-1-Yl)-Xanthines Compound
Aug, 2023

(10 months from now)

IN200500567P1 BOEHRINGER INGELHEIM 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds
Aug, 2023

(10 months from now)

IN243301B BOEHRINGER INGELHEIM 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds
Aug, 2023

(10 months from now)

EP1532149B9 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1532149A2 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1532149B1 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines Nov, 2025

(3 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors May, 2027

(4 years from now)

US11033552 BOEHRINGER INGELHEIM DPP IV inhibitor formulations May, 2027

(4 years from now)

US9486526 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy Aug, 2029

(6 years from now)

US10034877 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy Aug, 2029

(6 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor Jun, 2030

(7 years from now)

US8853156 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy Mar, 2031

(8 years from now)

Drugs and Companies using LINAGLIPTIN ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with sulfonlyurea; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone; method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone); Method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone); method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin; Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and who are ineligible for metformin therapy by administering linagliptin; Treatment of type 2 diabetes mellitus in a patient with renal impairment and for whom metformin therapy is inappropriate by administering linagliptin without dose adjustment; Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and for whom metformin therapy is inappropriate by administering linagliptin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.